ARS Pharmaceuticals (SPRY) to Release Quarterly Earnings on Thursday

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect ARS Pharmaceuticals to post earnings of ($0.35) per share and revenue of $7.48 million for the quarter.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The company reported $0.52 earnings per share for the quarter, beating analysts' consensus estimates of ($0.04) by $0.56. The company had revenue of $86.58 million for the quarter, compared to the consensus estimate of $15.46 million. On average, analysts expect ARS Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

ARS Pharmaceuticals Trading Up 2.1 %

SPRY stock traded up $0.30 during trading on Friday, hitting $14.46. The company had a trading volume of 1,028,217 shares, compared to its average volume of 1,180,693. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of -28.35 and a beta of 0.86. The business has a 50 day moving average of $12.81 and a 200 day moving average of $13.04. ARS Pharmaceuticals has a fifty-two week low of $7.55 and a fifty-two week high of $18.51.

Analysts Set New Price Targets

SPRY has been the topic of a number of research analyst reports. Scotiabank began coverage on shares of ARS Pharmaceuticals in a research note on Friday, March 7th. They set a "sector outperform" rating and a $30.00 price objective on the stock. William Blair reiterated an "outperform" rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. Raymond James upped their price objective on ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a "strong-buy" rating in a report on Tuesday, January 14th. Leerink Partners raised their target price on ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an "outperform" rating in a research note on Monday, January 13th. Finally, Oppenheimer assumed coverage on shares of ARS Pharmaceuticals in a research report on Monday, February 10th. They issued an "outperform" rating and a $40.00 price target on the stock. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $31.00.

Insider Transactions at ARS Pharmaceuticals

In related news, Director Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $12.31, for a total value of $615,500.00. Following the transaction, the director now owns 210,346 shares of the company's stock, valued at approximately $2,589,359.26. This trade represents a 19.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Eric Karas sold 10,000 shares of the firm's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $14.00, for a total transaction of $140,000.00. Following the completion of the transaction, the insider now owns 7,696 shares of the company's stock, valued at approximately $107,744. The trade was a 56.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 159,602 shares of company stock valued at $1,926,541 over the last three months. Company insiders own 40.10% of the company's stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.